Pivotal Receives Notification of Allowance for U.S. Patent Related to Combination VASCAZEN® and Cholesterol Absorption Inhibitor

Pivotal Therapeutics Inc [Pressemappe]
Woodbridge, Ontario (ots/PRNewswire) – Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), (“Pivotal” or the “Company”), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease and overall health, announced that … Lesen Sie hier weiter…